LEADER 06354nam 22009733u 450 001 9910139555703321 005 20230725051122.0 010 $a1-283-24049-1 010 $a9786613240491 010 $a1-4443-4257-6 010 $a1-4443-4254-1 035 $a(CKB)2550000000045840 035 $a(EBL)819297 035 $a(OCoLC)759159254 035 $a(SSID)ssj0000633398 035 $a(PQKBManifestationID)12245060 035 $a(PQKBTitleCode)TC0000633398 035 $a(PQKBWorkID)10619848 035 $a(PQKB)11067818 035 $a(MiAaPQ)EBC819297 035 $a(EXLCZ)992550000000045840 100 $a20131104d2011|||| u|| | 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aClinical Dilemmas in Inflammatory Bowel Disease$b[electronic resource] $eNew Challenges 205 $a2nd ed. 210 $aHoboken $cWiley$d2011 215 $a1 online resource (286 p.) 300 $aDescription based upon print version of record. 311 $a1-4443-3454-9 327 $aClinical Dilemmas inInflammatoryBowel Disease; Contents; Contributors; Preface; Part I: Genes and Phenotype in IBD; 1 Which will take us further in IBD-study of coding variation or epigenetics?; 2 IBD in different ethnic groups: same or different?; Part II: Bugs and IBD-Good, Bad, or Indifferent?; 3 How does the risk of infection influence management of IBD around the world?; 4 Traveling with IBD; 5 What to do about hepatitis B and hepatitis C in patients with IBD; 6 CMV in IBD-passenger or pathogen?; 7 Clostridium difficile in IBD: impact, prevention, and treatment 327 $a8 Prebiotics and synbiotics: panacea or placebo9 Worms: light at the end of their burrow; 10 Do we really need to vaccinate all patients with IBD?; Part III: Investigating IBD; 11 Biomarkers in IBD: myth or marvel?; 12 Radiation exposure in IBD: how do we minimize the dangers?; 13 Surveillance colonoscopy in UC: what is the best way to do it?; Part IV: Medical Therapy; 5-ASA; 14 New 5-ASAs for ulcerative colitis: a tiny step or giant stride forward?; 15 Do 5-ASAs prevent cancer?; 16 Why do we still use 5-ASAs in Crohn's disease?; Steroids 327 $a17 Steroids in Crohn's disease: do the benefits outweigh the dangers?Immunomodulators; 18 Thioguanine nucleotide measurement: nonadherent, underdosed, shunter, or refractory?; 19 Thiopurines and the sun: what should be done?; 20 Do thiopurines worsen risk and prognosis of cervical neoplasia?; 21 Optimizing use of methotrexate; 22 Which calcineurin inhibitor and when?; Biologics; 23 Are all anti-TNF agents the same?; 24 One drug or two: do patients on biologics need concurrent immunomodulation?; 25 How do we identify patients needing early aggressive therapy and what should we use? 327 $a26 What is the role of biologics in UC?27 What can we do with Crohn's patients who fail or lose response to anti-TNF therapy?; 28 Which extraintestinal manifestations of IBD respond to biologics?; 29 Use and abuse of biologics in pregnancy; 30 Is anti-TNF therapy safe to use in people with a history of malignancy?; 31 The risks of immunomodulators and biologics: what should we tell patients?; 32 When, how, and in whom should we stop biologics?; Part V: Other Treatments; 33 Avoiding drug interactions 327 $a34 Is there still a role for ursodeoxycholic acid treatment patients with inflammatory bowel disease associated with primary sclerosing cholangitis?35 Stem cell transplantation for Crohn's: will it fulfill its promise?; 36 Complementary therapy: is there a needle in the haystack?; Part VI: Surgical Dilemmas in IBD; 37 Optimizing IBD patients for surgery and recovery; 38 Is surgery the best initial treatment for limited ileocecal Crohn's disease?; 39 Laparoscopic or open surgery for IBD?; 40 Optimizing management of perianal Crohn's disease 327 $a41 Does anti-TNF therapy increase the risk of complications of surgery? 330 $aThe second edition of Clinical Dilemmas in Inflammatory Bowel Disease: New Challenges, is a practical, up-to-date handbook providing expert guidance on specific clinical dilemmas and areas of difficulty that the gastroenterologist regularly faces in day-to-day practice. In this new edition, 75% of the "dilemmas" are brand new dilemmas facing the IBD specialist concerning emerging treatment therapies, such as the use of cannabinoids and Viagra for Crohn's disease. The remaining 25% of the dilemmas are fully updated from the previous edition, incorporating the latest clinical thinking 606 $aClinical dilemmas 606 $aInflammatory bowel diseases 606 $aInflammatory Bowel Diseases 606 $aInflammatory bowel diseases - Decision making 606 $aInflammatory bowel diseases -- Decision making 606 $aInflammatory bowel diseases$xDecision making 606 $aInflammatory bowel diseases 606 $aIntestinal Diseases 606 $aGastroenteritis 606 $aGastrointestinal Diseases 606 $aDigestive System Diseases 606 $aDiseases 606 $aInflammatory Bowel Diseases 606 $aMedicine$2HILCC 606 $aHealth & Biological Sciences$2HILCC 606 $aGastroenterology$2HILCC 615 4$aClinical dilemmas. 615 4$aInflammatory bowel diseases. 615 4$aInflammatory Bowel Diseases. 615 4$aInflammatory bowel diseases - Decision making. 615 4$aInflammatory bowel diseases -- Decision making. 615 0$aInflammatory bowel diseases$xDecision making 615 0$aInflammatory bowel diseases 615 2$aIntestinal Diseases 615 2$aGastroenteritis 615 2$aGastrointestinal Diseases 615 2$aDigestive System Diseases 615 2$aDiseases 615 2$aInflammatory Bowel Diseases 615 7$aMedicine 615 7$aHealth & Biological Sciences 615 7$aGastroenterology 676 $a616.344 700 $aIrving$b Peter$0956256 701 $aSiegel$b Corey A$0956257 701 $aRampton$b David$0457140 701 $aShanahan$b Fergus$0909421 801 0$bAU-PeEL 801 1$bAU-PeEL 801 2$bAU-PeEL 906 $aBOOK 912 $a9910139555703321 996 $aClinical Dilemmas in Inflammatory Bowel Disease$92165084 997 $aUNINA LEADER 03947nam 2201057 a 450 001 9910812005803321 005 20230126210124.0 010 $a0-520-95532-3 024 7 $a10.1525/9780520955325 035 $a(CKB)2670000000324869 035 $a(EBL)1105926 035 $a(OCoLC)823577505 035 $a(SSID)ssj0000803666 035 $a(PQKBManifestationID)11438459 035 $a(PQKBTitleCode)TC0000803666 035 $a(PQKBWorkID)10811247 035 $a(PQKB)10048779 035 $a(StDuBDS)EDZ0000155603 035 $a(MiAaPQ)EBC1105926 035 $a(OCoLC)833386508 035 $a(MdBmJHUP)muse31061 035 $a(DE-B1597)519297 035 $a(DE-B1597)9780520955325 035 $a(Au-PeEL)EBL1105926 035 $a(CaPaEBR)ebr10642601 035 $a(CaONFJC)MIL423759 035 $a(EXLCZ)992670000000324869 100 $a20120628d2013 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aNew Orleans suite$b[electronic resource] $emusic and culture in transition /$fLewis Watts and Eric Porter 210 $aBerkeley $cUniversity of California Press$dc2013 215 $a1 online resource (225 p.) 300 $aDescription based upon print version of record. 311 $a0-520-27388-5 311 $a0-520-27387-7 320 $aIncludes bibliographical references and index. 327 $aNew Orleans, America, music -- Reflections on Jazz Fest 2006 -- Parading against violence -- Reconstruction's soundtrack -- To reinvent life. 330 $aWith New Orleans Suite, Eric Porter and Lewis Watts join the post-Katrina conversation about New Orleans and its changing cultural scene. Using both visual evidence and the written word, Watts and Porter pay homage to the city, its region, and its residents, by mapping recent and often contradictory social and cultural transformations, and seeking to counter inadequate and often pejorative accounts of the people and place that give New Orleans its soul. Focusing for the most part on the city's African American community, New Orleans Suite is a story about people: how bad things have happened to them in the long and short run, how they have persevered by drawing upon and transforming their cultural practices, and what they can teach us about citizenship, politics, and society. 606 $aPopular music$xSocial aspects$zLouisiana$zNew Orleans 606 $aHurricane Katrina, 2005$xSocial aspects 610 $aafrican american. 610 $aamerican community. 610 $aanthropology. 610 $aartists. 610 $aaudience. 610 $abiopolitical. 610 $abrass band. 610 $acitizenship. 610 $acity life. 610 $acongo square. 610 $acreole. 610 $acreolization. 610 $acrowded cities. 610 $acultural practices. 610 $acultural scene. 610 $acultural transformations. 610 $acultural. 610 $aengaging. 610 $aentertainment industry. 610 $ahistorical. 610 $ahistory. 610 $ahurricane katrina. 610 $ajazz music. 610 $amusic history. 610 $amusic. 610 $anew orleans. 610 $apage turner. 610 $aperforming arts. 610 $apop culture. 610 $aregional studies. 610 $asocial issues. 610 $asociety. 610 $asociology. 610 $aus cities. 610 $avisual evidence. 615 0$aPopular music$xSocial aspects 615 0$aHurricane Katrina, 2005$xSocial aspects. 676 $a306.4/84240976335 700 $aWatts$b Lewis$f1946-$01619418 701 $aPorter$b Eric$g(Eric C.)$0707262 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910812005803321 996 $aNew Orleans suite$93951626 997 $aUNINA